A Phase 2, Long-Term Safety Study of GS-6624 in Adult Subjects With Idiopathic Pulmonary Fibrosis (IPF)

Trial Profile

A Phase 2, Long-Term Safety Study of GS-6624 in Adult Subjects With Idiopathic Pulmonary Fibrosis (IPF)

Discontinued
Phase of Trial: Phase II

Latest Information Update: 10 Apr 2017

At a glance

  • Drugs Simtuzumab (Primary)
  • Indications Idiopathic pulmonary fibrosis
  • Focus Adverse reactions
  • Acronyms ATLAS
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 25 Feb 2016 Status changed from active, no longer recruiting to discontinued, according to ClinicalTrials.gov record.
    • 23 Sep 2015 Planned End Date changed from 1 Jun 2019 to 1 Jan 2018 as reported by the ClinicalTrial.gov record.
    • 23 Sep 2015 Planned primary completion date changed from 1 Jun 2019 to 1 Jan 2018 as reported by the ClinicalTrial.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top